Clinical use of p53 in Barrett's esophagus

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 7, 2006, Pages 1243-1249

  Keswani, Rajesh N ^a   Noffsinger, Amy ^a   Waxman, Irving ^a   Bissonnette, Marc ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CELL CYCLE; CELL DEATH; DISEASE COURSE; DYSPLASIA; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY; SIGNAL TRANSDUCTION;

BARRETT ESOPHAGUS; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746441430     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0010     Document Type: Short Survey

References (69)

1. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
2. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-42.
3. Winters C, Jr., Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
5. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86.
6. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
7. Spechler SJ. Should patients with GERD be screened once at least for Barrett's epithelium? A balancing view: to screen or not to screen: scoping out the issues. Am J Gastroenterol 2004;99:2295-6.
8. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-9.
9. Lao CD, Simmons M, Syngal S, et al. Dysplasia in Barrett esophagus. Cancer 2004;100:1622-7.
10. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005;54 Suppl 1:i6-12.
11. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360:1587-9.
12. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
13. Nowell PC. Tumor progression: a brief historical perspective. Semin Cancer Biol 2002;12:261-6.
14. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999;50:23-6.
15. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
16. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
18. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
19. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 rumour antigen to band 17p13. Nature 1986;320:84-5.
20. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
21. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
22. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003;116:4077-85.
23. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408: 307-10.
24. Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761-9.
25. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
26. Doak SH, Jenkins GJ, Parry EM, et al. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer 2003;89:1729-35.
27. Carlson N, Lechago J, Richter J, et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 2002;97:1340-5.
28. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002;99:2948-53.
29. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-6.
30. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997;15:1001-10.
31. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg 1997;225:17-30.
32. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
33. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-50.
34. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
35. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-7.
36. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
37. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
38. Casson AG, Manolopoulos B, Troster M, et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 1994;167:52-7.
39. Moore JH, Lesser EJ, Erdody DH, Natale RB, Orringer MB, Beer DG. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 1994;56:487-93.
40. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
41. Tockman MS, Gupta PK, Pressman NJ, Mulshine JL. Considerations in bringing a cancer biomarker to clinical application. Cancer Res 1992;52:2711-8s.
42. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
43. Blount PL, Ramel S, Raskind WH, et al. 17p Allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991;51:5482-6.
44. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
45. Jones DR, Davidson AG, Summers CL, Murray GF, Quinlan DC. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 1994;57:598-603.
46. Polkowski W, van Lanschot JJ, Ten Kate FJ, et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995;4:163-71.
47. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220-8.
48. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994;35:764-8.
49. Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995;175:175-80.
50. Neshat K, Sanchez CA, Galipeau PC, et al. p53 Mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
51. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 2001;14:397-403.
52. Novotna K, Trkova M, Pazdro A, et al. TP53 gene mutations are rare in nondysplastic Barrett's esophagus. Dig Dis Sci 2006;51:110-3.
53. Ross A, Kinney T, Larghi A, Stearns L, Dye C, Waxman I. Complete circumferential endoscopic mucosal resection as a treatment for early esophageal carcinoma or Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2005;61:AB95.
54. Conio M, Cameron AJ, Chak A, Blanchi S, Filiberti R. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett's oesophagus. Lancet Oncol 2005;6:311-21.
55. Feith M, Stein HJ, Mueller J, Siewert JR. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 2004;17:322-7.
56. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996;93:7081-4.
57. Giaretti W. Aneuploidy mechanisms in human colorectal preneoplastic lesions and Barrett's esophagus. Is there a role for K-ras and p53 mutations? Anal Cell Pathol 1997;15:99-117.
58. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
59. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-42.
60. Younes M, Ertan A, Lechago LV, Somoano JR, Lechago J. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
61. Gimenez A, de Haro LM, Parrilla P, Bermejo J, Perez-Guillermo M, Ortiz MA. Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett esophagus and mild histologic alterations. Arch Pathol Lab Med 1999;123:1260-3.
62. Skacel M, Petras RE, Rybicki LA, et al. p53 Expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002;97:2508-13.
63. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
64. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
65. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
66. Dolan K, Walker SJ, Gosney J, Field JK, Button R. TP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus 2003;16:83-9.
67. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
68. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
69. Reid BJ. p53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2001;96:1321-3.